1 |
Di Stefano G, Fiume L, Baglioni M, Bolondi L, Busi C, Chieco P, Kratz F, Manaresi F, Pariali M. 2006. A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade. Liver Int 26: 726-733.
DOI
|
2 |
Yakovlev AG, Di Giovanni S, Wang G, Liu W, Stoica B, Faden AI. 2004. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem 279: 28367-28374.
DOI
|
3 |
Sladowski D, Steer SJ, Clothier RH, Balls M. 1993. An improved MTT assay. J Immunol Methods 157: 203-207.
DOI
ScienceOn
|
4 |
Lambert JD, Elias RJ. 2010. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys 501: 65-72.
DOI
|
5 |
Elbling L, Weiss RM, Teufelhofer O, Uhl M, Knasmueller S, Schulte-Hermann R, Berger W, Micksche M. 2005. Green tea extract and (-)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities. FASEB J 19: 807-816.
|
6 |
Chan MM, Soprano KJ, Weinstein K, Fong D. 2006. Epigal-locatechin- 3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 207: 389-396.
DOI
ScienceOn
|
7 |
Sadzuka Y, Sugiyama T, Suzuki T, Sonobe T. 2001. Enhancement of the activity of doxorubicin by inhibition of glutamate transporter. Toxicol Lett 23: 159-167.
|
8 |
Wetzel CC, Berberich SJ. 2001. p53 binds to cisplatin-damaged DNA. Biochim Biophys Acta 1517: 392-397.
DOI
ScienceOn
|
9 |
Gupta S, Hussain T, Mukhtar H. 2003. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cells cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 410: 177-185.
DOI
|
10 |
Lin JK. 2002. Cancer chemoprevention by tea polyphenolsthrough modulating signal transduction pathways. ArchPharm Res 25: 561-571.
DOI
|
11 |
Scalbert A, Manach C, Morand C, Remesy C, Jimenez L.2005. Dietary polyphenols and the prevention of diseases.Crit Rev Food Sci Nutr 45: 287-306.
DOI
|
12 |
Sorenson S, Glimelius B, Nygren P. 2001. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol 40: 327-339.
DOI
|
13 |
Matsuyama R, Reddy S, Smith TJ. 2006. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24: 3490-3496.
DOI
|
14 |
Hogberg T, Glimelius B, Nygren P. 2001. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 40: 340-360.
DOI
|
15 |
Crown JP. 2001. The platinum agents: a role in breast cancer treatment? Senmin Oncol 28: 28-37.
|
16 |
Comella P, Abate G, Di Finizio G, Daponte A, Zarrilli D. 1990. Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin. Cancer Chemother Pharmacol 26: 306-309.
DOI
|
17 |
Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D. 2004. Antitumor activity of a new platinum (II) complex with low nephrotoxicity and genotoxicity. Chem Biol Interact 148: 37-48.
DOI
|
18 |
Samad A, Sultana Y, Aqil M. 2007. Liposomal drug delivery systems: an update review. Curr Drug Deliv 4: 297-305.
DOI
|
19 |
Cersosimo RJ. 1993. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother 27: 438-441.
DOI
|
20 |
Kartalou M, Essigmann JM. 2001. Mechanisms of resistance to cisplatin. Mutat Res 478: 23-43.
DOI
ScienceOn
|
21 |
Kanadaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, HuangYT, Lee MT. 2005. The antitumor activities of flavonoids.In Vivo 19: 895-909.
|
22 |
Graham HN. 1992. Green tea composition, consumption, andpolyphenol chemistry. Prev Med 21: 334-350.
DOI
|